American Society of Hirudotherapy

Aqueous Extract of Whitmania Pigra Whitman Alleviates Thrombus Burden Via Sirtuin 1/NF-κB Pathway

Preclinical pharmacology published in J Surg Res (2019)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Preclinical (animal)Salivary PharmacologyDrug DevelopmentYao XL et al. · The Journal of surgical research, 2019

Abstract

BACKGROUND: Whitmania pigra Whitman (W pigra), a traditional Chinese medicine, has functions of breaking stagnant and eliminating blood stasis. The aim of this study was to investigate the underlying mechanism of W pigra against deep vein thrombosis (DVT). METHODS: A rat model of DVT induced by inferior vena cava stenosis was successfully established. Rats were administered vehicle (saline solution, p.o.), three doses of W pigra aqueous extract (34.7, 104.2, or 312.5 mg crude W pigra/kg, p.o.), heparin (200 U/kg, i.v.), or clopidogrel (25 mg/kg, p.o.) once daily for 2 d. Thrombus weight and histopathological changes were examined. Blood samples were collected to determine blood cell counts, blood viscosity, blood coagulation, blood fibrinolysis, serum levels of interleukin-1β, and tumor necrosis factor-α. Protein expressions of Sirtuin1 (SIRT1), acetylated p65 (Ace-p65), and phosphorylated p65 (p-p65) were determined by Western blot. Furthermore, SIRT1-specific inhibitor EX527 was applied to confirm the role of SIRT1 in the antithrombotic effect of W pigra. RESULTS: W pigra significantly decreased thrombus weight. W pigra had no effects on blood cell counts, whole blood viscosity, blood coagulation, blood fibrinolysis. However, it reduced tissue factor protein expression in the vein wall and thrombus. Moreover, it sharply increased SIRT1 protein expression and decreased leukocytes recruitment in the thrombus and vein wall, serum levels of interleukin-1β and tumor necrosis factor-α, and protein expressions of Ace-p65 and p-p65. Furthermore, the antithrombotic effect of W pigra was significantly abolished by EX527. CONCLUSIONS: Aqueous extract of W pigra effectively reduced DVT burden by inhibiting inflammation via SIRT1/nuclear factor-kappa B signaling pathway.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleResearch Support, Non-U.S. Gov't
Indexed MeSH termsAnimalsBiological ProductsCarbazolesCytokinesDrug Evaluation, PreclinicalFemaleInflammationLeechesMaleMedicine, Chinese TraditionalNF-kappa BRats, Sprague-Dawley

Summary

Aqueous extract of Whitmania pigra alleviated thrombus burden in a rat inferior-vena-cava-stenosis model by activating Sirtuin 1 and suppressing NF-κB, with reduced inflammatory cytokines.

Why This Matters for Hirudotherapy

This study investigated the mechanism by which aqueous extract of Whitmania pigra Whitman—a traditional Chinese medicine—reduces deep vein thrombosis (DVT) burden in a rat model of inferior vena cava stenosis. The abstract reports that W pigra extract significantly decreased thrombus weight, increased SIRT1 protein expression, and reduced inflammatory markers (interleukin-1β, tumor necrosis factor-α, acetylated p65, phosphorylated p65) and leukocyte recruitment, with the antithrombotic effect abolished by the SIRT1 inhibitor EX527. Notably, the extract had no effects on blood cell counts, viscosity, coagulation, or fibrinolysis. For ASH, the relevance is indirect: the abstract does not identify W pigra taxonomically as a leech, and findings are limited to a rat model without human data.

Citation

Aqueous Extract of Whitmania Pigra Whitman Alleviates Thrombus Burden Via Sirtuin 1/NF-κB Pathway.

Yao XL et al. · The Journal of surgical research, 2019

Added to ASH library: May 26, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.